Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Artivion, Inc. (NYSE: AORT), a medical device company focused on cardiac and vascular surgery and the treatment of aortic diseases. Through these filings, investors can review Artivion’s detailed financial statements, risk disclosures, material agreements and governance information.
Artivion’s periodic reports on Forms 10-K and 10-Q describe its business, which includes aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, as well as preservation services for cardiac and vascular tissues. These filings outline segment-level information, geographic reach and key risk factors associated with its aortic-focused product portfolio and international operations.
Current reports on Form 8-K document material events such as quarterly financial results, amendments to the company’s credit and guaranty agreement, real estate purchase contracts for manufacturing and office facilities, and executive leadership changes. For example, recent 8-K filings discuss an amendment that extended the maturity of term loan and revolving credit facilities and added a secured delayed draw term loan facility, as well as agreements to purchase properties supporting On-X manufacturing operations in Austin, Texas.
On Stock Titan, Artivion’s SEC filings are updated in near real time as they are posted to EDGAR. AI-powered summaries help explain complex sections of lengthy documents, such as credit agreement amendments, non-GAAP reconciliations, and detailed risk factor discussions. Investors can quickly locate annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K), and use AI-generated highlights to understand how new filings may relate to Artivion’s aortic device portfolio, clinical programs, capital structure and corporate strategy.
Artivion, Inc. senior vice president and general counsel Jean F. Holloway reported both stock sales and an equity award in company shares. On February 23–24, 2026, she sold a total of 4,747 shares of common stock at prices of $37.588 and $35.693 per share.
Footnotes state these sales were automatically executed to cover tax withholding owed upon vesting of performance and restricted stock units, and are not discretionary trades. She also received a grant of 20,085 shares of restricted stock at no cost, which vest in three equal annual installments starting on the first anniversary of the grant date.
ARTIVION, INC. President & CEO James P. Mackin reported both automatic tax-related sales and an equity award of common stock. On February 23–24, he sold a total of 34,898 shares at prices around $35.69–$37.59 in pre-arranged “sell to cover” transactions to pay tax withholding on vesting performance and restricted stock units, which the company notes were not discretionary trades. On February 24, he also received a grant of 97,030 shares of restricted stock at no purchase price, vesting 33 1/3% per year starting on the first anniversary of the grant under the Equity and Cash Incentive Plan. Following these transactions, Mackin directly holds 863,125 shares of Artivion common stock.
Artivion, Inc. executive Lance A. Berry reported routine equity compensation activity. On February 23 and 24, he sold 4,981 and 4,485 shares of common stock at $37.588 and $35.693 per share, respectively, to cover tax withholding triggered by vesting of performance and restricted stock units, which the company notes were non-discretionary “sell to cover” transactions.
On February 24, he also acquired a grant of 37,482 shares of restricted stock at no cost, which vest in equal thirds annually starting on the first anniversary of the grant date under the Equity and Cash Incentive Plan. Following these transactions, his directly held common stock increased to 181,447 shares.
Artivion, Inc.’s Chief Commercial Officer John E. Davis reported a mix of stock compensation activity and related tax sales. He received a grant of 20,438 shares of restricted stock, which vest in equal thirds each year starting on the first anniversary of the grant date.
To cover tax withholding from vesting performance and restricted stock units, 5,848 shares were automatically sold in open-market transactions at prices of about $35.69 and $37.59 per share, described as non-discretionary “sell to cover” sales. After these transactions, Davis directly owns 209,306 shares of common stock.
AORT filed a notice under Section 144 reporting an intended sale of 2,075 common shares tied to restricted stock vesting on 02/23/2026.
The filing also discloses a prior sale of 3,773 common shares on 02/23/2026 for $141,817.64, and identifies Fidelity Brokerage Services LLC as the broker on 02/24/2026.
AORT reported a proposed resale of 4,485 shares of common stock. The filing states these 4,485 shares arise from restricted stock vesting received as compensation on 02/23/2026.
The filing also lists 4,981 shares of common stock sold during the prior three months on 02/23/2026, with an aggregate amount of $187,223.34.
Jean Holloway filed a Form 144 indicating an intended sale of 1,668 shares of common stock related to restricted stock vesting on 02/23/2026, with a reported aggregate value of $59,535.76.
The filing also reports prior sales during the past three months of 3,079 shares on 02/23/2026 with aggregate proceeds of $115,731.92.
AORT insider filing reports proposed and recent share dispositions by James P. Mackin. The notice lists a proposed sale of 13,936 common shares delivered on 02/23/2026 tied to restricted stock vesting and shows three reported sales in the prior three months: 30,921 shares on 12/02/2025 for $1,408,736.02, 30,921 shares on 12/03/2025 for $1,405,693.40, and 20,962 shares on 02/23/2026 for $787,909.17.
Marshall Stanton reported an intended sale of Common shares. The Form 144 lists 2,423 shares with a value of 91074.51 dated 02/23/2026. The entry is tied to Restricted Stock Vesting and classified as Compensation.
Amy Horton filed a Rule 144 notice reporting proposed and recent sales of common stock of AORT. The filing lists a proposed sale of 830 common shares on 02/23/2026 described as Restricted Stock Vesting (Issuer, Compensation). It also records prior sales of 4,572 shares on 12/08/2025 for $203,081.38 and 1,731 shares on 02/23/2026 for $65,063.96.